Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive rats
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
This study has administered pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone) or amiloride to attenuate the remodelling and associated functional changes, especially an increased cardiac stiffness, in DOCA‐salt hypertensive rats. In control rats, the elimination half‐life of pirfenidone following a single intravenous dose of 200 mg kg−1 was 37 min while oral bioavailability at this dose was 25.7%. Plasma pirfenidone concentrations in control rats averaged 1.9±0.1 μg ml−1 over 24 h after 14 days' administration as a 0.4% mixture in food. Pirfenidone (approximately 250 – 300 mg kg−1 day−1 as 0.4% in food) and amiloride (1 mg kg−1 day−1 sc) were administered for 2 weeks starting 2 weeks post‐surgery. Pirfenidone but not amiloride attenuated ventricular hypertrophy (2.69±0.09, UNX 2.01±0.05. DOCA‐salt 3.11±0.09 mg kg−1 body wt) without lowering systolic blood pressure. Collagen deposition was significantly increased in the interstitium after 2 weeks and further increased with scarring of the left ventricle after 4 weeks; pirfenidone and amiloride reversed the increases and prevented further increases. This accumulation of collagen was accompanied by an increase in diastolic stiffness constant; both amiloride and pirfenidone reversed this increase. Noradrenaline potency (positive chronotropy) was decreased in right atria (neg log EC50: control 6.92±0.06; DOCA‐salt 6.64±0.08); pirfenidone but not amiloride reversed this change. Noradrenaline was a more potent vasoconstrictor in thoracic aortic rings (neg log EC50: control 6.91±0.10; DOCA‐salt 7.90±0.07); pirfenidone treatment did not change noradrenaline potency. Thus, pirfenidone and amiloride reverse and prevent cardiac remodelling and the increased cardiac stiffness without reversing the increased vascular responses to noradrenaline. British Journal of Pharmacology (2002) 135, 961–968; doi:10.1038/sj.bjp.0704539
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Cited by
THE CARDIAC FIBROBLAST: Therapeutic Target in Myocardial Remodeling and Failure
Brown, R. D., Ambler, S. K., Mitchell, M. D., & Long, C. S. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095802 · Cited by 647
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454
Function, structure and therapeutic potential of complement C5a receptors
Monk, P. N., Scola, A., Madala, P., & Fairlie, D. P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707332 · Cited by 404
Domanski, M., Norman, J., Pitt, B., Haigney, M., Hanlon, S., & Peyster, E. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00765-4 · Cited by 337
Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease
Gourdie, R. G., Dimmeler, S., & Kohl, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.89 · Cited by 332
Metadata
- Authors
- Mirkovic, S., Seymour, A. L., Fenning, A., Strachan, A., Margolin, S. B., Taylor, S. M., & Brown, L.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2002-02
- Volume
- 135
- Issue
- 4
- Pages
- 961-968
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2029023549
- Cited by
- 130
- References
- 1
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive rats. https://app.cochat.ai/papers/10.1038/sj.bjp.0704539
- The paper
- Mirkovic, S., Seymour, A. L., Fenning, A., Strachan, A., Margolin, S. B., Taylor, S. M., & Brown, L. (2002). Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA‐salt hypertensive rats. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0704539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.